Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2

Journal of the National Cancer Institute

Volumn 105, Issue 16, 2013, Pages 1230-1238

  Barton, Debra L ^a   Liu, Heshan ^a   Dakhil, Shaker R ^b   Linquist, Breanna ^a   Sloan, Jeff A ^a   Nichols, Craig R ^c   McGinn, Travis W ^d   Stella, Philip J ^e   Seeger, Grant R ^f   Sood, Amit ^a   Loprinzi, Charles L ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^c Virginia Mason Health System   (United States)

^d Upstate Carolina CCOP   (United States)

^e Michigan Cancer Research Consortium   (United States)

^f Altru Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; PLACEBO;

ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; CANCER FATIGUE; CANCER SURVIVOR; CANCER THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GINSENG; HUMAN; INSOMNIA; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PAIN; PANAX QUINQUEFOLIUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; VOMITING;

ADULT; AGED; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PANAX; PHYTOTHERAPY; PLANT EXTRACTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883177002     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt181     Document Type: Article

References (52)

1. Arndt V, Stegmaier C, Ziegler H, et al. A population-based study of the impact of specific symptoms on quality of life in women with breast cancer 1 year after diagnosis. Cancer. 2006;107(10):2496-2503.
2. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer. 2006;106(4):751-758.
3. Harrington CB, Hansen JA, Moskowitz M, et al. It's not over when it's over: long-term symptoms in cancer survivors-a systematic review. Int J Pych Med. 2010;40(2):163-181.
4. Hofman M, Ryan JL, Figueroa-Moseley CD, et al. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(Suppl 1):4-10.
5. Molassiotis A, Zheng Y, Denton-Cardew L, et al. Symptoms experienced by cancer patients during the first year from diagnosis: patient and informal caregiver ratings and agreement. Palliat Support Care. 2010;8(3):313-324.
6. Purcell A, Fleming J, Bennett S, et al. A multidimensional examination of correlates of fatigue during radiotherapy. Cancer. 2010;116(2):529-537.
7. Fulton C, Knowles G. Cancer fatigue. Eur J Cancer Care (Engl). 2000;9(3):167-171.
8. Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage. 2009;38(5):650-662.
9. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006;24(13):2073-2078.
10. Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial.J Clin Oncol. 2010;28(23):3673-3679.
11. Auret KA, Schug SA, Bremner AP, et al. A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. J Pain Symptom Manage. 2009;37(4): 613-621.
12. Butler JM Jr, Case LD, Atkins J, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo- methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol. 2007;69(5):1496-1501.
13. Mar Fan HG, Clemons M, Xu W, et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer. 2008;16(6):577-583.
14. Bruera E, Yennurajalingam S, Perez-Cruz PE, et al. Methylphenidate (MP) and nursing telephone intervention (NTI) for cancer-related fatigue (CRF) in advanced cancer patients: a double-blind randomized phase II trial [published online ahead of print May 20, 2013]. J Clin Oncol.
15. Escalante C, Meyers C, Reuben J, et al. A randomized, double-blind, placebo-controlled crossover trial of a sustained release methylphenidate in cancer-related fatigue. J Clin Oncol. 2012;30(Suppl.):abstract 9072.
16. Morrow CJ, Ghattas M, Smith C, et al. Src family kinase inhibitor saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. Cancer Res. 2010;70(14):5931-5941.
17. Bruera E, El Osta B, Valero V, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2007;25(23):3475-3481.
18. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003;21(24):4635-4641.
19. Cruciani RA, Dvorkin E, Homel P, et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. J Pain Symptom Manage. 2009;37(4):622-631.
20. Lesser GJ, Case D, Stark N, et al. A randomized, double-blind, placebo-controlled study of oral coenzyme Q(10) to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol. 2013;11(1):31-42.
21. Campos MPdO, Riechelmann R, Martins LC, et al. Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J Altern Complem Med. 2011;17(6):505-512.
22. Natural Standard Monograph, Ginseng. http://naturalstandard.com/ naturalstandard/monographs.
23. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol. 1999;58(11):1685-1693.
24. Cui J. Identification and quantification of ginsenosides in various commercial ginseng preparations. Eur J Pharm Sci. 1995;3:77-85.
25. Tadano T, Nakagawasai O, Niijima F, et al. The effects of traditional tonics on fatigue in mice differ from those of the antidepressant imi-pramine: a pharmacological and behavioral study. Am J Chinese Med. 2000;28(1):97-104.
26. Jin Y, Hofseth AB, Cui X, et al. American ginseng suppresses colitis through p53-mediated apoptosis of inflammatory cells. Cancer Prev Res (Phila). 2010;3(3):339-347.
27. Kang A, Hao H, Zheng X, et al. Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy. J Neuroinflammation. 2011;8:100.
28. Yang CS, Ko SR, Cho BG, et al. The ginsenoside metabolite compound K, a novel agonist of glucocorticoid receptor, induces tolerance to endotoxin-induced lethal shock. J Cell Mol Med. 2008;12(5A):1739-1753.
29. Wang LC, Lee TF. Effect of ginseng saponins on exercise performance in non-trained rats. Planta Med. 1998;64(2):130-133.
30. Wang X, Sakuma T, Asafu-Adjaye E, et al. Determination of ginsenosides in plant extracts from Panax ginseng and Panax quinquefolius L. by LC/MS/MS. Anal Chem. 1999;71(8):1579-1584.
31. Banerjee U, Izquierdo JA. Antistress and antifatigue properties of Panax ginseng: comparison with piracetam. Acta Physiol Lat Am. 1982;32(4):277-285.
32. Younus J, Collins A, Wang X, et al. A double blind placebo controlled pilot study to evaluate the effects of ginseng on fatigue and quality of life in adult chemo-naive cancer patients. J Clin Oncol. 2003;22(4):733.
33. Barton DL, Soori GS, Bauer BA, et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer. 2010;18(2):179-187.
34. Therneau TM. How many stratification factors are "too many" to use in a randomization plan? Control Clin Trials. 1993;14(2):98-108.
35. Stein KD, Jacobsen PB, Blanchard CM, et al. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage. 2004;27(1):14-23.
36. Curran S, Andrykowsky M, Studts J. Short form of the Profile of Mood States (POMS-SF): psychometric information. Psychol Assess. 1995;7(1):80-83.
37. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186-1196.
38. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
39. Dhruva A, Dodd M, Paul SM, et al. Trajectories of fatigue in patients with breast cancer before, during, and after radiation therapy. Cancer Nursing. 2010;33(3):201-212.
40. Donovan KA, Jacobsen PB, Andrykowski MA, et al. Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. J Pain Symptom Mange. 2004;28(4):373-380.
41. Sloan JA, Frost MH, Berzon R, et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 2006;14(10):988-998.
42. Bower JE, Ganz PA, Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med. 2005;67(2):277-280.
43. Bower JE, Ganz PA, Aziz N, et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4):604-611.
44. Bower JE, Ganz PA, Dickerson SS, et al. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology. 2005;30(1):92-100.
45. Schubert C, Hong S, Natarajan L, et al. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun. 2007;21(4):413-427.
46. Thornton LM, Andersen BL, Blakely W P. The pain, depression, and fatigue symptom cluster in advanced breast cancer: covariation with the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Health Psychol. 2010;29(3):333-337.
47. King ML, Murphy LL. American ginseng (Panax quinquefolius L.) extract alters mitogen-activated protein kinase cell signaling and inhibits proliferation of MCF-7 cells. J Exp Ther Oncol. 2007;6(2):147-155.
48. Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine. 2000;7(4):273-282.
49. Duda RB, Taback B, Kessel B, et al.: pS2 expression induced by American ginseng in MCF-7 breast cancer cells. Ann Surg Oncol. 1996;3(6):515-520.
50. Duda RB, Kang SS, Archer SY, et al. American ginseng transcription-ally activates p21 mRNA in breast cancer cell lines. J Korean Med Sci. 2001;16(Suppl):S54-S60.
51. King ML, Adler SR, Murphy LL. Extraction-dependent effects of American ginseng (Panax quinquefolium) on human breast cancer cell proliferation and estrogen receptor activation. Integr Cancer Ther. 2006;5(3):236-243.
52. Duda RB, Zhong Y, Navas V, et al. American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J Surg Oncol. 1999;72(4):230-239.